FIELD: biotechnology.
SUBSTANCE: the invention relates to the field of biotechnology. A group of inventions is described that includes an anti-VEGF-A antibody conjugate, a pharmaceutical composition for treating or preventing an ophthalmic disease, a method for treating or preventing an ophthalmic disease that comprises administering an effective amount of an antibody conjugate or a pharmaceutical composition, and a method for producing an antibody conjugate. In one embodiment of the invention, the antibody conjugate includes an anti-VEGF-A antibody and a polymer containing phosphorylcholine, where the polymer has a molecular weight of approximately 300,000 to approximately 175,000 Da, and the antibody conjugate has a molecular weight of between approximately 450,000 and 1,900,000 Da.
EFFECT: the invention expands the arsenal of remedies against VEGF-A.
46 cl, 7 tbl, 17 ex, 28 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PRODRUG COMPOSITIONS BASED ON CROSS-LINKED HYALURONIC ACID HYDROGEL AND METHODS OF THEIR PRODUCTION | 2018 |
|
RU2812787C2 |
| ANTI-BV8 ANTIBODIES AND USING THEM | 2010 |
|
RU2559542C2 |
| OPTIMIZED ANTIBODY COMPOSITIONS FOR TREATMENT OF EYE DISEASES | 2018 |
|
RU2782355C2 |
| HUMANISED ANTIBODIES AGAINST CD79b AND IMMUNOCONJUGATES AND METHODS OF APPLICATION | 2008 |
|
RU2557319C2 |
| OPTIMIZED OPTIONS OF ANTI-VEGF ANTIBODIES | 2016 |
|
RU2763916C2 |
| NOVEL ANTIBODIES | 2008 |
|
RU2490277C2 |
| ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | 2016 |
|
RU2757815C2 |
| ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS FOR USING THEM | 2009 |
|
RU2553566C2 |
| MULTISPECIFIC ANTIBODIES, THEREOF ANALOGUES, COMPOSITIONS AND METHODS | 2010 |
|
RU2580038C2 |
| ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS FOR USING THEM | 2008 |
|
RU2511410C2 |
